Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  BOARD MEETINGS
Board Meetings      
Medplus Health Services Ltd.
Source DateBoard Meeting DateDetails
10-Jul-2025 02-Aug-2025 Quarterly Results
25-Mar-2025 27-May-2025 Audited Results
08-Jan-2025 31-Jan-2025 Quarterly Results
10-Oct-2024 12-Nov-2024 Quarterly Results
27-Jun-2024 02-Aug-2024 Quarterly Results
01-Apr-2024 28-May-2024 Audited Results
16-Feb-2024 21-Feb-2024 Inter alia, to discuss the management recommendation to not proceed with the approval for Qualified Institutional Placement (QIP) received from shareholders on November 30, 2023.
27-Dec-2023 02-Feb-2024 Quarterly Results
25-Oct-2023 08-Nov-2023 Quarterly Results (Revised)
18-Oct-2023 26-Oct-2023 Quarterly Results
06-Oct-2023 11-Oct-2023 Inter alia, to consider and evaluate proposal for raising of funds by the Company, by way of inter alio, issue of equity shares or any other equity linked instruments or securities including convertible preference shares/ fully or partly convertible debentures or by way of a composite issue of non-convertible debentures and warrants entitling the warrant holder(s) to apply for equity shares, or any other eligible securities through inter alio, a private placement (including one or more qualified institutions placements) or further public issue of equity/ debt securities, preferential issue or a rights issue or through any other permissible mode under applicable laws and/ or combination thereof, as may be considered appropriate, subject to such statutory/regulatory/other approvals as may be required, including the approval of the members, to seek their consent for such fund raising and to approve ancillary actions for such fund raising. The Board, would further convene an Extra-ordinary General Meeting or postal ballot to obtain the approval of shareholders for the above proposal, once approved by the Board.
03-Oct-2023 05-Oct-2023 Inter alia, to consider and approve the Proposal for raising of funds by the Company
10-Jul-2023 07-Aug-2023 Quarterly Results (Revised)
07-Jul-2023 01-Aug-2023 Quarterly Results
03-May-2023 25-May-2023 Audited Results
25-Apr-2023 11-May-2023 Inter alia, to consider for approval of Members through Postal Ballot for the following business by way of Special Resolution: i. Approval for extending benefits of Employees Stock Option Plan 2023. to the employees of its Subsidiary Companies; and ii. Alteration of Articles of Association of the Company in relation to retain the Nomination Rights of the Promoters/Investors as per existing Articles of Association of the Company
13-Jan-2023 03-Feb-2023 Quarterly Results
10-Oct-2022 11-Nov-2022 Quarterly Results
04-Aug-2022 10-Aug-2022 Quarterly Results
23-May-2022 30-May-2022 Audited Results
Page 1 of 2
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.